Golden Biotechnology (4132) Stock Overview
Operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
4132 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Golden Biotechnology Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$12.00 |
| 52 Week High | NT$19.60 |
| 52 Week Low | NT$9.98 |
| Beta | 0.69 |
| 1 Month Change | -10.45% |
| 3 Month Change | -11.44% |
| 1 Year Change | -33.52% |
| 3 Year Change | -80.30% |
| 5 Year Change | -73.30% |
| Change since IPO | -67.57% |
Recent News & Updates
Shareholder Returns
| 4132 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 3.4% | 2.8% | 4.4% |
| 1Y | -33.5% | -3.0% | 18.0% |
Return vs Industry: 4132 underperformed the TW Biotechs industry which returned -3.9% over the past year.
Return vs Market: 4132 underperformed the TW Market which returned 15.9% over the past year.
Price Volatility
| 4132 volatility | |
|---|---|
| 4132 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.2% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4132's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 4132's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Li Yu Wu | www.goldenbiotech.com/en |
Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, as well as hypercholesterolemia and hyperlipidemia.
Golden Biotechnology Corporation Fundamentals Summary
| 4132 fundamental statistics | |
|---|---|
| Market cap | NT$1.95b |
| Earnings (TTM) | -NT$314.93m |
| Revenue (TTM) | NT$44.58m |
Is 4132 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4132 income statement (TTM) | |
|---|---|
| Revenue | NT$44.58m |
| Cost of Revenue | NT$55.77m |
| Gross Profit | -NT$11.19m |
| Other Expenses | NT$303.74m |
| Earnings | -NT$314.93m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.94 |
| Gross Margin | -25.10% |
| Net Profit Margin | -706.41% |
| Debt/Equity Ratio | 148.4% |
How did 4132 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 07:42 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Golden Biotechnology Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.